
Crash dummies used in car safety tests are still modeled after men despite higher risks for women
'It was a head-on crash and they were closest to the point of contact,' said Kuhn, now 25, who missed a semester of college to recover from the 2019 collision that caused her seat belt to slide off her hips and rupture her intestines by pinning them against her spine. 'That was an early clue that something else was going on.'
When Kuhn returned home to Maine, she found an article her grandma had clipped from Consumer Reports and left on her bed. Women are 73% more likely to be injured in a frontal crash, she learned, yet the dummy used in vehicle tests by the National Highway Traffic Safety Administration dates back to the 1970s and is still modeled almost entirely off the body of a man.
A survivor becomes an activist
Kuhn, who is starting law school at New York University this fall, took action and founded the nonprofit Drive US Forward. Its aim was to raise public awareness and eventually encourage members of Congress to sign onto a bill that would require NHTSA to incorporate a more advanced female dummy into its testing.
The agency has the final word on whether cars get pulled from the market, and the kind of dummy used in its safety tests could impact which ones receive coveted five-star ratings.
'It seems like we have an easy solution here where we can have crash test dummies that reflect an average woman as well as a man,' Sen. Deb Fischer, a Nebraska Republican who has introduced the legislation the past two sessions, told The Associated Press.
Senators from both parties have signed onto Fischer's 'She Drives Act,' and the transportation secretaries from the past two presidential administrations have expressed support for updating the rules.
But for various reasons, the push for new safety requirements has been moving at a sluggish pace. That's particularly true in the U.S., where much of the research is happening and where around 40,000 people are killed each year in car crashes.
Evolution of a crash test dummy
The crash test dummy currently used in NHTSA five-star testing is called the Hybrid III, which was developed in 1978 and modeled after a 5-foot-9, 171-pound man (the average size in the 1970s but about 29 pounds lighter than today's average). What's known as the female dummy is essentially a much smaller version of the male model with a rubber jacket to represent breasts. It's routinely tested in the passenger seat or the back seat but seldom in the driver's seat, even though the majority of licensed drivers are women.
'What they didn't do is design a crash test dummy that has all the sensors in the areas where a woman would be injured differently than a man,' said Christopher O'Connor, president and CEO of the Farmington Hills, Michigan-based Humanetics Group, which has spent more than a decade developing and refining one.
A female dummy from Humanetics equipped with all of the available sensors costs around $1 million, about twice the cost of the Hybrid used now.
But, O'Connor says, the more expensive dummy far more accurately reflects the anatomical differences between the sexes — including in the shape of the neck, collarbone, pelvis, and legs, which one NHTSA study found account for about 80% more injuries by women in a car crash compared to men.
Such physical dummies will always be needed for vehicle safety tests, and to verify the accuracy of virtual tests, O'Connor said.
Europe incorporated the more advanced male dummy developed by Humanetics' engineers, the THOR 50M (based on a 50th percentile man), into its testing procedures soon after Kuhn's 2019 crash in Ireland. Several other countries, including China and Japan, have adopted it as well.
But that model and the female version the company uses for comparison, the THOR 5F (based on a 5th percentile woman), have been met with skepticism from some American automakers who argue the more sophisticated devices may exaggerate injury risks and undercut the value of some safety features such as seat belts and airbags.
A debate over whether more sensors mean more safety
Bridget Walchesky, 19, had to be flown to a hospital, where she required eight surgeries over a month, after a 2022 crash near her home in Sheboygan, Wisconsin, that killed her friend, who was driving. While acknowledging the seat belt likely saved her life, Walchesky said some of the injuries — including her broken collarbone — were the result of it pinning her too tightly, which she views as something better safety testing focused on women could improve.
'Seat belts aren't really built for bodies on females,' Walchesky said. 'Some of my injuries, the way the force hit me, they were probably worsened.'
The Alliance for Automotive Innovation, an industry trade group, said in a statement to the AP that the better way to ensure safety — which it called its top priority — is through upgrades to the existing Hybrid dummy rather than mandating a new one.
'This can happen on a faster timeline and lead to quicker safety improvements than requiring NHTSA to adopt unproven crash test dummy technology,' the alliance said.
Humanetics' THOR dummies received high marks in the vehicle safety agency's early tests. Using cadavers from actual crashes to compare the results, NHTSA found they outperformed the existing Hybrid in predicting almost all injuries — including to the head, neck, shoulders, abdomen and legs.
A separate review by the Insurance Institute for Highway Safety, a research arm funded by auto insurers, was far more critical of the dummy's ability to predict chest injuries in a frontal crash. Despite the vast expansion in the number of sensors, the insurance institute's testing found, the male THOR dummy was less accurate than the current Hybrid dummies, which also had limitations.
'More isn't necessarily better,' said Jessica Jermakian, senior vice president for vehicle research at IIHS. 'You also have to be confident that the data is telling you the right things about how a real person would fare in that crash.'
Wednesdays
Columnist Jen Zoratti looks at what's next in arts, life and pop culture.
The slow pace of changing the rules
NHTSA's budget plan commits to developing the female THOR 5F version with the ultimate goal of incorporating it into the testing. But there could be a long wait considering the THOR's male version adopted by other countries is still awaiting final approval in the U.S.
A 2023 report by the Government Accountability Office, which conducts research for Congress, cited numerous 'missed milestones' in NHTSA's development of various crash dummy enhancements — including in the THOR models.
Kuhn acknowledges being frustrated by the slow process of trying to change the regulations. She says she understands why there's reluctance from auto companies if they fear being forced to make widespread design changes with more consideration for women's safety.
'Fortunately, they have very skilled engineers and they'll figure it out,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Vancouver Sun
6 hours ago
- Vancouver Sun
U.S. Batten disease experts who lobbied B.C. to reinstate drug in Charleigh Pollock case had relationships with drug company
Almost all the U.S. research experts the B.C. government leaned on to make a decision to reinstate a $800,000-a-year drug treatment for a 10-year-girl have, or had, relationships with the pharmaceutical company that manufacturers the drug or foundations that advocate for treatment, a Postmedia examination has found. The province's decision went against its own 58-member advisory committee. Of the 12 physicians and one neuroscientist who signed a letter sent to B.C. Health Minister Josie Osborne calling on treatment to be reinstated, eight of the signatories have declared conflicts in the past five years in papers written for scientific journals or for public presentations because they have consulted for, been paid by, or received grants from California-based BioMarin Pharmaceutical Inc. Another doctor reported being a consultant for BioMarin for four years on a resumé posted online and was paid by BioMarin to be on a medical podcast. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. BioMarin manufactures Brineura used to treat Batten disease, the rare incurable neurodegenerative condition that 10-year-old B.C. girl Charleigh Pollock has. Three other doctors who signed the letter have relationships with foundations that advocate and raise money for Batten disease research. The Postmedia examination also found that one of the U.S. doctors that signed the letter owns shares in BioMarin, two have been quoted in BioMarin news releases and three former BioMarin employees sit on one of the U.S.-based Batten research foundations. Experts in bioethics and pharmaceutical policy say the conflict-of-interest revelations raise questions on why the B.C. government overruled its own advisory committee, why it depended on the opinions of U.S. doctors with relationships to BioMarin, and whether it took those conflict-of-interest relationships into consideration. 'I want to suggest that the British Columbia Ministry of Health was handling this case in an ethically justifiable way and has been sidetracked by the lobbying efforts of the Batten disease patient advocacy groups and the patient herself and the doctors whose careers stand to benefit from licensing and prescribing this drug,' said Arthur Schafer, a University of Manitoba professor with a speciality in bioethics and founder of the school's centre for professional and applied ethics. In an emailed statement from communications manager Amy Crofts, the B.C. Ministry of Health said they 'can confirm that government was aware that some of the U.S. experts have conflicts of interest.' Officials noted the conflicts were required to be declared when publishing peer-reviewed research on Batten disease, including the initial clinical trials on Brineura that were funded by BioMarin and used by Canada's Drug Agency in 2019 to establish the discontinuation criteria. Health officials did not respond to questions on whether the government considered the conflicts of interest in their assessment and how it weighed these conflicts against the advice of its own adviser group. Osborne was not made available for an interview. Initially, the B.C. government backed its advisory committee's decision to halt treatment to the 10-year-old girl after six years. The advisory committee said they recommended stopping treatment because discontinuation criteria was met, and beyond which the benefits versus risks of the drug were not believed to be favourable. The U.S. doctors sent a letter — under a Batten disease support and research association designation — outlining their concerns and calling for the girl's treatment to continue. Osborne, the health minister, said the province reversed its decision because of the letter. 'The letter I received today from the Batten disease experts confirms there is a significant disagreement between health experts on Brineura, and it is not acceptable that Charleigh and her family suffer as a result of that disagreement about the use of Brineura for Batten disease,' Osborne said last month. Following the reversal, 10 members of the advisory committee quit and B.C. Premier David Eby has now called for a review and overhaul of the decision process. Schafer, who has been studying biomedical conflicts of interest for more than 20 years, said he was not surprised to learn the U.S. letter signatories had relationships with the drug company that produced the drug and that they recommended its continued use. He said he believes the B.C. government would have been fully aware of the conflicts of interests held by the U.S. doctors who signed the letter, as these relationships are 'standard procedure.' Schafer, who formerly worked as an ethics consultant for the Winnipeg Regional Health Authority, said he believes the B.C. government capitulated and caved to pressure, as he believes most Canadian provincial governments would. 'And I think the resulting decision is not morally justifiable,' he said. Schafer noted the effectiveness of these expensive rare-disease drugs is often unproven, underscoring the importance for governments to have independent expert advice when making difficult decisions in the face of emotion, public pressure and scarce resources. Other experts have made similar observations. Pierre-Marie David, a professor in the faculty of pharmacy at the University of Montreal who has been researching access to exceptional drugs, said a key to making these decisions is building trust in provincial health agencies, particularly given there is a large pipeline of these expensive drugs with uncertain effectiveness for rare diseases, which means more difficult decisions and increasing costs. 'If we have trust in the decision of a public agency, we should stick to it,' said David. He said he did not believe provinces and Canada should be turning for advice to the U.S. health system, whether the doctors there are right or wrong, or have a conflict of interest or not, because they do not have a public health care system like Canada's. 'They have no lessons to tell us here,' said David. The relationships of some of the U.S. letter signatories to BioMarin are laid out in conflict-of-interest and disclosure statements in scientific journals. For example, a 2024 editorial Dr. Raymond Wang wrote for the journal Neurology includes a 'disclosure' that says he receives research funding from, has received speaking honorariums from, and owns equity in BioMarin Pharmaceuticals, which manufacturers Brineura. Wang is director of the Batten Disease Center for Excellence at Children's Hospital of Orange County in California. A 2024 Lancet Neurology journal article co-written by Dr. Emily de los Reyes includes a conflict-of-interest statement that notes she received 'salary support' from BioMarin for herself and her research personnel. She also received honorariums and travel support. De los Reyes is the chair of the Batten Disease Centers of Excellence program and director of the Batten Disease Center of Excellence at Nationwide Children's Hospital in Columbus, Ohio. A 2022 Journal of Inherited Metabolic Disease paper co-authored by Dr. Erika Augustine, who is the director of the Batten Disease Centre of Excellence at the Kennedy Krieger Institute in Baltimore, notes in a conflict-of-interest statement that she received compensation as a consultant for BioMarin and other pharmaceutical companies. Postmedia reached out by email to these doctors to ask questions about the conflict-of-interest disclosures, but did not receive a reply. In a written response to Postmedia questions, Amy Fenton Parker, president of the Batten Disease Support and Research Association, said questions of funding from drug companies should be posed to each research and clinical treatment group. 'In all scientific presentations, both groups are required to make disclosures about any funding or conflicts of interest,' noted Parker. She noted the centres of excellence do not receive funding from industry partners through the association. There are a number of Batten disease organizations that co-operate and partner to advocate for, and help fund, research for treatments. The Batten Disease Support and Research Association manages the centres of excellence program, under which the U.S. doctors who signed the letter operate. That association has three former BioMarin employees on its board of directors , including vice-chair Barbara Wuebbels. Another group, the Beyond Batten Disease Foundation, has raised $35 million to help fund research to find treatments and has partnered with the Batten Disease Support and Research Association. The research association has several chapters around the world, including in Canada. The 10-year-old B.C. girl's mother, Jori Fales, is on the board of directors of the Canadian chapter, according to the latest filing of the group for registered charities in Canada. ghoekstra@


Cision Canada
7 hours ago
- Cision Canada
The Mufflerman Inc. announces recapitalization and rebranding
TORONTO, Aug. 13, 2025 /CNW/ - The Mufflerman Inc., a portfolio company of Argyle Capital Partners Management Inc. ("Argyle") has undertaken a recapitalization and rebranding, culminating in the creation of ASG Auto Service Repair Group Inc. ("The Auto Service Group") and an exit of Argyle from the investment. The Mufflerman was built through six acquisitions and now consists of six brands, 29 locations across Ontario and is focused on the service and repair of cars, light vans, trucks and fleets. Going forward the group will be rebranded to Auto Service Group with all individual brands continuing operations with no changes. The recapitalization was led by the existing operational management team of Glenn Gatcliffe (Director), and Costa Haitas (President) who will continue to provide leadership to The Auto Service Group. The transaction was financed by original investors, participation of new investors and with the support of Toronto-Dominion Bank and BDC Capital Inc. Costa Haitas, President of The Auto Service Group said, "We are thrilled to be entering a new stage in our growth and evolution. Over the last 4.5 years Argyle Capital Partners have provided tremendous strategic vision and leadership. Along with our entire team of over 155 employees, Glenn and I would like to thank Argyle, and we look forward to continued success in building The Auto Service Group into one of the preeminent automotive aftermarket companies in Canada. We are well positioned to continue our M&A strategy, integrating new businesses into our purpose built operational and capital infrastructure." About Auto Service Group: About Argyle Capital Partners: Founded in 2016, Argyle Capital Partners is a Toronto-based private equity firm focused on partnering with family-owned businesses in Canada's lower middle market. Argyle invests in traditional businesses in industrial products, manufacturing, distribution, and business services.


Cision Canada
7 hours ago
- Cision Canada
Argyle announces successful exit of its investment in The Mufflerman
TORONTO, Aug. 13, 2025 /CNW/ - Argyle Capital Partners Management Inc. ("Argyle") today announced the successful exit of its investment in The Mufflerman ("Mufflerman" or the "Company"), a leading automotive repair and maintenance provider, to ASG Auto Service Repair Group Inc. The transaction marks the conclusion of a highly successful 4.5-year investment, during which Argyle and its investor group generated, net of fees, a ~5x multiple of invested capital ("MOIC") and a ~45% internal rate of return ("IRR"). Mufflerman, based in London Ontario, operates a network of automotive repair locations under multiple banners across the province. Founded over 60 years ago, the Company has built a reputation for high-quality service and trusted local relationships. Argyle initially acquired the platform in early 2021. Over the hold period, Mufflerman evolved into one of Ontario's leading multi-store operators in the automotive aftermarket. The transformation was driven by a focused buy-and-build strategy, disciplined operational upgrades, and a capital structure purpose-built for growth. The Company benefitted from its senior leadership team, led by Costa Haitas and Argyle partner, Glenn Gatcliffe, who spearheaded efforts to professionalize operations, improve margin performance, and integrate new locations. As part of its M&A strategy, Argyle completed five tuck-in acquisitions, financed on balance sheet, enabling the business to triple its EBITDA during the investment period. "We're incredibly proud of what was accomplished with Mufflerman," said Mark MacPherson, Co-Founder and Managing Partner at Argyle. "This transaction is a clear example of Argyle's ability to identify and scale regional leaders through thoughtful M&A, hands-on operational support, and disciplined capital management. The Company is well-positioned for continued growth under its new ownership." About Argyle Founded in 2016, Argyle is a Toronto-based private equity firm focused on partnering with family-owned businesses in Canada's lower middle market. Argyle invests in traditional businesses in industrial products, manufacturing, distribution, and business services.